Drug Development
Nirsevimab lowered hospitalizations due to RSV-related lower respiratory tract disease by 83.21%. Friday’s data drop comes ahead of next week’s advisory committee meeting for Pfizer’s RSV hopeful.
FEATURED STORIES
Mixed headlines have plagued the cell and gene therapy space of late. We believe that a renewed case of optimism is not only warranted but essential if these therapies are to reach their full potential.
Through substantial leadership turnover and workforce cuts, the FDA has continued to support the advanced therapy sector, actively working to remove obstacles to innovation.
With immunology and inflammation blockbusters like AbbVie’s Skyrizi and Rinvoq reeling in nearly $7 billion combined in the third quarter, the pipeline-in-a-product strategy has never been more attractive.
Subscribe to ClinicaSpace
Clinical trial results, research news, the latest in cancer and cell and gene therapy, in your inbox every Monday
THE LATEST
AbbVie announced Friday that its investigational drug navitoclax, when used together with ruxolitinib, eases symptoms in myelofibrosis patients who had not yet been treated with a JAK inhibitor.
The European Hematology Association’s 2022 Hybrid Congress is in full swing in Vienna, Austria and will feature the newest and most promising developments in blood cancer research.
It was an extraordinarily busy week for clinical trial news and updates due to several prominent international conferences. Here’s a look at some of the highlights.
Owkin and BMS signed a deal to utilize Owkin’s artificial intelligence capabilities to carry out more targeted and efficient clinical trials on a wide range of therapeutic candidates.
Following a marathon session of the FDA’s Cell, Tissue and Gene Therapies Advisory Committee, bluebird bio passed its first critical hurdle in approval for the lentiviral vector gene therapy, eli-cel.
Cemdisiran, an RNAi mono-therapeutic intended to treat IgAN is poised to enter Phase III clinical studies after positive Phase II topline results were shared Thursday morning.
The annual meeting of the American Headache Society (AHS) is being held in Denver, Colorado from June 9-12. Here’s a look at just some of the wide-ranging research being presented.
The FDA plans to review changes to Novavax’s manufacturing process before it authorizes its vaccine.
Seelos Therapeutics announced in vitro data Thursday supporting its gene therapy, SLS-004. SLS-004 is intended for the treatment of dementia with Lewy bodies (DLB).
COVID-19 is turning out to be a particularly tenacious disease. And researchers are starting to understand why. Also, a new study found that COVID-19 deaths were higher in Republican-voting counties.